Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Director Michael Douglas Taylor Sells 7,500 Shares
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Director Michael Douglas Taylor sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $36.26, for a total value of $271,950.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at $271,950. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Michael Douglas Taylor also recently made the following trade(s):
- On Tuesday, August 13th, Michael Douglas Taylor sold 22,500 shares of Deciphera Pharmaceuticals stock. The stock was sold at an average price of $40.77, for a total value of $917,325.00.
Shares of NASDAQ DCPH traded down $0.23 during trading on Friday, hitting $37.09. The company had a trading volume of 579,474 shares, compared to its average volume of 1,593,771. The company has a market cap of $1.89 billion, a P/E ratio of -13.15 and a beta of 1.92. Deciphera Pharmaceuticals Inc has a 52 week low of $18.55 and a 52 week high of $42.99. The business’s 50-day moving average is $29.50 and its 200 day moving average is $25.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26.
A number of research firms have weighed in on DCPH. BidaskClub upgraded Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 16th. SunTrust Banks upped their target price on Deciphera Pharmaceuticals to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Leerink Swann restated a “positive” rating and issued a $29.00 target price (up from $20.00) on shares of Deciphera Pharmaceuticals in a research report on Wednesday, August 14th. Guggenheim upped their target price on Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. Finally, Deutsche Bank began coverage on Deciphera Pharmaceuticals in a research report on Thursday, July 18th. They issued a “buy” rating and a $42.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Deciphera Pharmaceuticals has an average rating of “Buy” and an average target price of $48.00.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE increased its holdings in shares of Deciphera Pharmaceuticals by 4.2% in the second quarter. Bank of America Corp DE now owns 26,052 shares of the company’s stock valued at $588,000 after buying an additional 1,062 shares in the last quarter. Bank of Montreal Can bought a new position in shares of Deciphera Pharmaceuticals in the second quarter valued at $28,000. BNP Paribas Arbitrage SA increased its holdings in shares of Deciphera Pharmaceuticals by 61,033.3% in the first quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock valued at $43,000 after buying an additional 1,831 shares in the last quarter. Virtus ETF Advisers LLC increased its holdings in shares of Deciphera Pharmaceuticals by 17.7% in the second quarter. Virtus ETF Advisers LLC now owns 12,449 shares of the company’s stock valued at $281,000 after buying an additional 1,871 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Deciphera Pharmaceuticals by 89.2% in the second quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock valued at $95,000 after buying an additional 1,913 shares in the last quarter. 59.80% of the stock is currently owned by institutional investors.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Further Reading: The basics of gap trading strategies
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.